News

Q2 2006 profit reached GBP1.32 billion ($2.45 billion), up from GBP1.16 billion for Q2 2005. Earnings per share (EPS) hit 23.3 pence, compared to 20.2 pence for Q2

Fumagillin – a drug that can inhibit the growth of new blood vessels that feed atherosclerotic plaques – was sent directly to the base of plaques by microscopically

A group of scientists conducted studies on rats with a class of drugs known as ampakines. Ampakines were developed in the early 1990s by University of California researchers

Bristol-Myers Squibb posted Q2 2006 net sales from continuing operations of $4.9 billion and net earnings from continuing operations of $667 million, or $0.34 per diluted share, compared

The data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in Genitope’s pivotal phase III clinical trial in follicular non-Hodgkin’s lymphoma (fNHL)

The therapeutic protein being licensed by Nostrum is known as clot-specific streptokinase (CSSK), which was developed at The Institute of Microbial Technology (IMTECH), an institute governed by the

In US National Institutes of Health-funded study, scientists found that Nexrutine, a proprietary extract from the bark of the Phellodendron tree, prevented the growth of prostate cancer cells.

Most hypertensive patients, especially those with other associated risk factors, now require multiple therapies using more than one drug to keep their blood pressure at desired levels. Fixed

Initial indications of this collaborative research agreement will focus on how to use knowledge of T-cell signaling pathways to design novel cancer therapeutics and broaden to other indications